Company Description
MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases.
The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren’s syndrome; AAV-GAD in Phase 2 trial for Parkinson’s disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4.
In addition, the company’s products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer’s disease, and wet and dry neovascular age related macular degeneration.
Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain.
The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson’s disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system.
MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 381 |
| CEO | Alexandria Forbes |
Contact Details
Address: 450 East 29th Street, 14th Floor New York, New York 10016 United States | |
| Phone | 646 860 7985 |
| Website | meiragtx.com |
Stock Details
| Ticker Symbol | MGTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001735438 |
| CUSIP Number | G59665102 |
| ISIN Number | KYG596651029 |
| Employer ID | 98-1448305 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alexandria Forbes Ph.D. | Chief Executive Officer, President and Director |
| Richard Brian Giroux B.A. | Chief Operating Officer and Chief Financial Officer |
| Dr. Stuart Naylor Ph.D. | Chief Development Officer |
| Robert J. Wollin J.D. | General Counsel and Secretary |
| Dr. Michel Michaelides M.D. | Head of Clinical Ophthalmology |
| Christine Elise Sheehy | Senior Vice President of Global Integration |
| Tim Randall | Senior Vice President of Risk and Internal Controls |
| Dr. Robert K. Zeldin M.D. | Chief Medical Officer |
| Dr. David Rubinstein Ph.D. | Senior Vice President of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 26, 2025 | 8-K | Current Report |
| Jun 17, 2025 | 8-K | Current Report |
| May 14, 2025 | SCHEDULE 13G/A | Filing |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| May 9, 2025 | 8-K | Current Report |
| Apr 30, 2025 | ARS | Filing |
| Apr 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 22, 2025 | 144 | Filing |